Arcus Biosciences, Inc. R&D Expense

Quick Answer

Arcus Biosciences, Inc. reported R&D Expense of $523.00 million for fiscal year 2025.

Arcus Biosciences, Inc. R&D Expense — Annual History

Fiscal Year R&D Expense YoY Change
2025 $523.00M +16.7%
2024 $448.00M +31.8%
2023 $340.00M +18.1%
2022 $288.00M +12.1%
2021 $257.00M +61.6%
2020 $159.00M +102.6%
2019 $78.48M +58.1%
2018 $49.65M +5.1%
2017 $47.22M +231.4%
2016 $14.25M

Quarterly R&D Expense

Quarter Ending R&D Expense YoY QoQ
September 30, 2025 $141.00M +14.6% +1.4%
June 30, 2025 $139.00M +20.9% +13.9%
March 31, 2025 $122.00M +11.9% -0.8%
September 30, 2024 $123.00M +50.0% +7.0%
June 30, 2024 $115.00M +36.9% +5.5%
March 31, 2024 $109.00M +34.6% +32.9%
September 30, 2023 $82.00M +6.5% -2.4%
June 30, 2023 $84.00M +20.0% +3.7%
  • Arcus Biosciences, Inc. showed an increase of +16.7% in R&D Expense compared to the prior fiscal year.
  • Over the 2016–2025 period, Arcus Biosciences, Inc.’s r&d expense has grown by 3570.9% (from $14.25 million to $523.00 million).
  • The most recent figure is from Arcus Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment